Active Biotech and its partner NeoTX announced that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox (naptumomab), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The phase IIa, open label trial in US will assess naptumomab in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics.